BC Environmental and Occupational Health Research Network

With a multitude of therapeutic options under investigation for multiple myeloma, the ability to identify those that show the most potential in treating the disease is of critical importance. One of the most effective and efficient ways to do this is through pre-clinical validation of targeted single-agent therapies as well as those in innovative, rationally-designed combinations and sequences. The Validation Awards were developed to advance the science of pre-clinical validation in multiple myeloma. Proposals may request up to $100,000 per year for 2 years.